Byrne Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Byrne Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.86K	Buy	+16	New	+$3.5K	﹤0.01%	523
2024 Q2	–	Sell	-9	Closed	-$1.08K	–	546
2024 Q1	$1.08K	Sell	9 -22	-71%	-$2.69K	﹤0.01%	512
2023 Q4	$3.79K	Sell	31 -15	-33%	-$1.87K	﹤0.01%	447
2023 Q3	$6K	Hold	46	–	–	0.01%	384
2023 Q2	$6K	Hold	46	–	–	﹤0.01%	449
2023 Q1	$7K	Hold	46	–	–	0.01%	424
2022 Q4	$7.33K	Sell	46 -10	-18%	-$1.47K	0.01%	409
2022 Q3	$7K	Sell	56 -50	-47%	-$7.6K	0.01%	379
2022 Q2	$17K	Sell	106 -74	-41%	-$11.4K	0.01%	302
2022 Q1	$28K	Hold	180	–	–	0.02%	267
2021 Q4	$23K	Buy	+180	New	+$23.7K	0.01%	279

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Byrne Asset Management's JAZZ Position: Q2 2026 in Review

Byrne Asset Management opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 16 shares worth $3.86K. The stake represents ﹤0.01% of the portfolio and ranks #523 among its holdings. This is a return to the name: Byrne Asset Management previously reported a position in JAZZ as recently as Q1 2024.

Byrne Asset Management first reported a position in JAZZ in Q4 2021 and has held it in 11 quarters since. The position peaked at $28K in Q1 2022. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Byrne Asset Management held 16 shares of Jazz Pharmaceuticals worth $3.86K as of Q2 2026.
Jazz Pharmaceuticals was a new Byrne Asset Management position in Q2 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Byrne Asset Management's portfolio in Q2 2026, its #523 holding.
Byrne Asset Management first reported a position in Jazz Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
Byrne Asset Management's Jazz Pharmaceuticals position peaked at $28K in Q1 2022.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Byrne Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.